PDF-Guidance for IRBs Clinical Investigators and Sponsors Considerations When Transf PDF document

S Department of Health and Human Services Food and Drug Administration Center for Drug Evaluatio n and Research Center for Biologics Evaluation and Research Center

Upload by stefany-barnette
Published on 2014-10-03

Presentation Embed Code

<iframe width="560" height="315" src="https://www.docslides.com/embed/2206" frameborder="0" allowfullscreen></iframe>

Download Presentation

Download Presentation The PPT/PDF document "Guidance for IRBs Clinical Investigators..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Guidance for IRBs Clinical Investigators and Sponsors Considerations When Transf: Transcript

PDF-Guidance for IRBs Clinical Investigators and Sponsors Considerations When Transf PDF document

Presentation Embed Code

Download Presentation

Guidance for IRBs Clinical Investigators and Sponsors Considerations When Transf: Transcript

Related Contents

Contains Nonbinding Recommendations Information Sheet Guidance For IRBs Clinical Investigators

Informed Consent Information Sheet Guidance for IRBs Clinical Investigators and Sponsors

Guidance for Clinical Investigators Sponsors and IRBs Investigational New Drug A

Guidance on legislation Clinical investigations of medical devices guidance for investigators

Guidance for Industry Considerations for the Design of Early Phase Clinical Trials of

Information Sheet Guidance for Sponsors Clinical Inves

Guidance for Sponsors, Institutional Review Boards, Clinical Investiga

CONSIDERATIONS Institutions Outside IRBs both the cent

Guidance for Industry Safety Considerations for Container Labels and Carton Labeling

Considerations in the Translation

Scientific Considerations in Demonstrating Biosimilarity to a Reference Product DRAFT

Steven Taylor Chief Executive Officer

C entral IRBs

Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants U